GlassScriptPhysician profile
Lucio MD Nobile
NPI 1396828588
$3,206.14
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $826 · 2021: $44.44 · 2022: $1,718 · 2023: $283 · 2024: $26.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $283 · Food and Beverage: $26.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $282.73 |
| Food and Beverage | $26.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $834.87 | 2020-2023 | |
| Pfizer INC. | $259.20 | 2019-2022 | |
| Janssen Biotech, INC. | $209.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $153.13 | 2020-2022 | |
| Incyte Corporation | $143.72 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $132.24 | 2020-2022 | |
| Amgen INC. | $109.89 | 2020-2022 | |
| Sobi, INC | $105.98 | 2022 | |
| Celgene Corporation | $105.15 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $99.41 | 2020 | |
| Rigel Pharmaceuticals, INC. | $76.13 | 2019-2022 | |
| Genentech USA, INC. | $62.12 | 2019-2022 | |
| Global Blood Therapeutics, INC. | $61.69 | 2020-2022 | |
| Glaxosmithkline, LLC. | $56.68 | 2020-2022 | |
| Puma Biotechnology, INC. | $54.04 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucio Nobile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.